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Background: Tetanus, diphtheria, acellular pertussis, inactivated polio (Tdap-IPV) vaccines administered dur-
ing pregnancy protect young infants from Bordetella pertussis (B. pertussis) infection. Whilst the impact of
maternal Tdap-IPV vaccination on infants’ humoral response to subsequent pertussis immunisation has been
investigated, little is known about any impact on innate responses.
Methods: We investigated the immune response to B. pertussis in mothers and infants from Tdap-IPV-vacci-
nated and unvaccinated pregnancies, utilising a whole blood assay and flow cytometric phenotyping of neo-
natal natural killer (NK) cells, monocytes and dendritic cells. Blood was collected from mother and umbilical
cord at birth, and from infants at seven weeks (one week pre-primary pertussis immunisation) and five
months of age (one month post-primary pertussis immunisation). 21 mothers and 67 infants were studied.
Findings: Vaccinated women had elevated pro-inflammatory cytokine responses to B. pertussis. At birth,
babies of vaccinated women had elevated IL-2 and IL-12 responses, elevated classical monocyte proportions,
and reduced monocyte and NK cell cytokine responses. The elevated IL-2 response persisted to seven weeks-
of-age, when lower IL-10 and IL-13 responses were also seen. One-month post-primary pertussis vaccina-
tion, infants from vaccinated pregnancies still had lower IL-10 responses to B. pertussis, as well as lower IL-4.
Interpretation: This study suggests that pertussis vaccination during pregnancy impacts infant cellular
immune responses, potentially contributing to the modification of antibody responses already reported fol-
lowing primary immunisation against B. pertussis.
Funding: National Institute for Health Research Imperial Biomedical Research Centre and IMmunising PReg-
nant women and INfants neTwork (funded by the GCRF Networks in Vaccines R&D).
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Bordetella pertussis (B. pertussis) is the causative agent of pertussis
disease, which has resurged in many countries in recent years, with a
disproportionate number of cases and fatalities in infants too young
to be vaccinated [15]. Globally, many countries including the UnitedKingdom, Belgium, the Czech Republic, the United States, Mexico,
Argentina, Brazil and Australia have introduced maternal immunisa-
tion programmes utilising tetanus, diphtheria, acellular pertussis vac-
cines with or without inactivated polio (Tdap-IPV and Tdap,
respectively) [69]. This vaccine strategy helps protect infants in the
first weeks of life through the transfer of antigen-specific maternal
antibodies across the placenta during pregnancy. Both maternal
Tdap-IPV [8,1012] and Tdap vaccination [1316], have been dem-
onstrated to be both safe and effective in pregnancy. Several studies
[1720], but not all [21], have demonstrated that maternal Tdap-IPV
immunisation during pregnancy blunts the offspring’s antibody
Research in context
Evidence before this study
Animal models of B. pertussis infection have demonstrated a key
role for the innate immune response in clearance of bacteria
and directing an effective adaptive response to infection. There
is little evidence regarding innate responses to B. pertussis
infection following tetanus, diphtheria, acellular pertussis, inac-
tivated polio (Tdap-IPV) vaccination, particularly in the context
of vaccination during pregnancy, which has become the fore-
most tool in preventing pertussis in young infants. Maternal
Tdap-IPV vaccination is associated with reduced infant anti-
body responses to primary pertussis vaccination.
Added value of this study
We present evidence that Tdap-IPV vaccination during preg-
nancy has effects on the maternal immune system beyond
boosting maternal antibody levels; vaccinated mothers had
increased cytokine responses to B. pertussis, compared to
unvaccinated mothers. We also show that Tdap-IPV given dur-
ing pregnancy is associated with modulation of infant immune
response to B. pertussis. Babies born to Tdap-IPV-vaccinated
mothers have an altered distribution of monocytes at birth, and
infants from vaccinated pregnancies showed differences in
some cytokine responses to B. pertussis at birth, seven weeks of
age and five months of age.
Implications of all the available evidence
Our findings suggest maternal Tdap-IPV may lead to modifica-
tion of the fetal immune system, in addition to the protection
provided by transfer of maternal antibodies. Further studies are
required to determine the clinical relevance of these observa-
tions, in terms of infant responses to infection or vaccination.
2 T.F. Rice et al. / EBioMedicine 72 (2021) 103612responses to primary pertussis immunisation. A recent study sug-
gested that maternal Tdap-IPV vaccination has no effect on infant T
and B cell responses to B. pertussis at birth [22]. The impact of mater-
nal Tdap-IPV on the infant innate immune response remains to be
determined.
Innate responses to B. pertussis are important in controlling infec-
tion in animal models. During infection in mice, natural killer (NK)
cells produce interferon (IFN)-g, which helps restrict B. pertussis to
the lungs [23] and mice lacking NK cells or the IFN-g receptor have
disseminated, lethal infections [23,24]. Murine dendritic cells (DCs)
secrete pro-inflammatory cytokines and chemokines in response B.
pertussis [25] and in addition, DCs also produce the anti-inflamma-
tory cytokine interleukin (IL)-10 in response to filamentous hemag-
glutinin (FHA) and lipopolysaccharide (LPS), promoting the induction
of regulatory T cells [25,26]. In humans, isolated NK cells produce
IFN-g in response to B. pertussis [27] and induction of cytokines that
advance T cell responses to infection in monocyte-derived DCs has
been shown [28]. These innate responses to B. pertussis therefore
both contribute to early restriction and innate clearance of B. pertussis
as well as programming of an effective adaptive response to infection,
including the induction of specific T helper cell subsets.
Following maternal inactivated influenza vaccination, influenza-
specific effector memory T cells have been observed in cord blood
[29] suggesting vaccines given to the mother during pregnancy may
prime the fetal immune system in utero. In contrast, a study of mater-
nal pertussis vaccination during pregnancy in Brazil found that T cell
cytokine responses to B. pertussis in cord blood are unaffected by
Tdap-IPV vaccination status of the mother [22]. This discrepancycould be due to the distinct immunogenicity induced by the high-
dose inactivated flu vaccine versus the Tdap subunit vaccine used in
these studies. Indeed, the acellular pertussis components of Tdap-IPV
vaccines have been implicated in the modulation of immune
responses by dampening early cytokine responses [26,3032]. Poten-
tial priming or dampening effects of Tdap-IPV vaccination during
pregnancy requires further investigation.
Pregnancy and early-life are periods of significant immune modu-
lation and vulnerability to infection. It is therefore important to
understand if maternal vaccination could impact the newborn’s
innate immune system. Here, we investigated early cytokine/chemo-
kine responses to the B. pertussis bacterium and to Tdap-IPV vaccine




Pregnant women vaccinated with a tetanus, diphtheria, acellular
pertussis, inactivated polio-containing combination vaccine (Tdap-
IPV), in line with vaccine policy in the United Kingdom, were
recruited to the study between 2014 and 2018 [21]. The vaccine
given was initially Repevax (Sanofi Pasteur, Lyon, France), with a
switch to Boostrix-IPV (GlaxoSmithKline, Wavre, Belgium) after July
2014. Unvaccinated pregnant women were recruited over the same
time-period. Infants received three doses of acellular pertussis con-
taining-vaccine (tetanus, diphtheria, acellular pertussis, inactivated
polio, Hib) at 8, 12 and 16 weeks; DTaP5-IPV-Hib (Pediacel; Sanofi
Pasteur) or DTaP3-IPV-Hib (Infanrix-IPV-Hib; GlaxoSmithKline),
according to the United Kingdom national immunisation program.9
Maternal vaccine contents are as follows: Repevax contains DTx
(2Lf), TTx (5Lf), PTx (2.5mg), FHA (5mg), Prn (3mg), FIM 2 and 3 (5mg)
and inactivated poliovirus. Boostrix-IPV contains DTx (2.5 Lf), TTx (5
Lf), PTx (8mg), FHA (8mg), Prn (2.5mg) and inactivated poliovirus.
Infant vaccines contents are as follows: Pediacel (Sanofi Pasteur,
France) contains DTx (25Lf), TTx (10Lf), PTx (20mg), FHA (20mg), Prn
(3mg), FIM 2 and 3 (5mg), inactivated poliovirus and Haemophilus
influenzae type b polysaccharide (Hib). Infanrix-IPV-Hib contains
DTx (25Lf), TTx (10Lf), PTx (25mg), FHA (25mg), Prn (8mg), inacti-
vated poliovirus and Hib.
2.2. Study subjects and sample collection
Women with singleton, uncomplicated term pregnancies booked for
maternity care at Imperial College Healthcare NHS Trust were recruited
antenatally. Exclusion criteria included multiple pregnancy, chronic dis-
eases including diabetes, maternal autoimmune disease, blood-borne
infections (hepatitis B, HIV and syphilis), hypertension, congenital abnor-
malities, gestational diabetes and pre-eclampsia. Pregnant women that
met the inclusion criteria for the study andmet none of the exclusion cri-
teria were approached for recruitment. Vaccination status, including the
gestation at time of vaccination was recorded at time of recruitment, and
again at the time of birth. Pregnantwomen in our study classed as unvac-
cinated never received a pertussis vaccine during pregnancy. Blood sam-
ples were collected from the mother within 12 h of delivery and from
the umbilical cord immediately following birth. Venous blood was col-
lected from infants at seven weeks (one week pre-primary pertussis
immunisation) and five months of age (one month post-primary pertus-
sis immunisation).
2.3. Ethics
The study was ethically approved by the London-Hampstead
Research Ethics Committee (13/LO/1712) and the National Health
Service (NHS) Health Research Authority gave approval for the study
T.F. Rice et al. / EBioMedicine 72 (2021) 103612 3to take place within Imperial College NHS Trust. Written informed
consent was obtained from all women, who also consented for their
babies to participate.
2.4. Bacteria and antigens
B. pertussis (B1917, isolated in 2000) was obtained via the Dutch
National Surveillance System from patients with confirmed whoop-
ing cough [33]. B. pertussis was cultured in Thalen-Ijssel (THIJS)
medium and heat-inactivated by incubating for 30 min at 56°C, as
previously described [34,35]. Purified B. pertussis antigens pertactin
(Prn), filamentous hemagglutinin (FHA) and pertussis toxin (Ptx)
were a gift from the Centre for Infectious Disease Control, National
Institute for Public Health and the Environment (RIVM), the Nether-
lands [36].
2.5. Whole blood bacterial stimulation assay
Whole blood collected into sodium heparin vacutainer tubes
(Becton Dickinson, UK) was diluted 1:10 in RPMI medium supple-
mented with 10% fetal calf serum (FCS; Thermo Fisher Scientific, UK)
and 1% penicillin-streptomycin (Sigma-Aldrich, UK). Blood was stim-
ulated with heat-killed B. pertussis in 96 well plates at a final concen-
tration of 5 £ 105 colony forming units per 100ml of diluted blood
volume, within two hours of collection. Media alone and 1mg/ml LPS
(L2137, from Salmonella Minnesota, Sigma, UK) served as negative
and positive controls, respectively. The concentrations of bacteria
and LPS were optimised in control experiments using bloods from
non-pregnant volunteers, and then in maternal and cord blood sam-
ples to ensure cytokine responses were within the detectable range
for each assay. Plates were incubated at 37°C, 5% CO2 for 24 h, after
which supernatant was removed and stored at -80°C.
2.6. Quantification of early cytokines in culture supernatants
Cytokine concentrations in the supernatants from whole blood
assays were determined by multiplex assay (Meso Scale Discovery,
USA). Briefly, supernatants were diluted 1:10 with assay-specific dil-
uent and 100ml added to plates pre-coated with capture antibodies
for ten cytokines/chemokines: IFN-g , IL-1b, IL-2, IL-4, IL-6, (IL-8), IL-
10, IL-12p70, IL-13 and TNF-a. After incubation with shaking for two
hours, detection antibodies for each cytokine (except IL-8) were
added and further incubated with shaking for two hours. Read buffer
was added to each well and plates were read using a MESO QuickPlex
SQ 120. Data produced was analysed using Discovery Workbench 4.0.
We did not add the detection antibody for IL-8, as this was consis-
tently out of range for detection. Therefore, IL-8 was measured sepa-
rately by ELISA (IL-8 Human ELISA kit, Invitrogen, UK) following the
manufacturer’s instructions. Singleplex ELISAs were also used to
detect IL-6, IL-1b and IL-10 responses (all Human ELISA kit, Invitro-
gen, UK) in cord blood in a series of assays where plasma was
removed from whole blood prior to stimulation, and replaced with
media or pooled cord blood serum. ELISA plates were read at 450nm
using a VersaMax Microplate reader (Molecular Devices, UK) and
SoftMaxPro 7.
2.7. Phenotyping of cord blood innate immune cells
Peripheral blood mononuclear cells (PBMCs) were isolated from
fresh whole umbilical cord blood using Histopaque (Sigma-Aldrich,
UK) and cryopreserved in FCS supplemented with 10% dimethyl sulf-
oxide (Sigma-Aldrich, UK). Cryopreserved PBMCs were rapidly
thawed and live cells counted by trypan blue exclusion. Aliquots with
less than 80% viability were discarded. PBMCs were added to 96-well
round-bottom culture plates at 4 £ 105 cells/well in 200ml RPMI
(with 10% FCS, 1% penicillin-streptomycin). Cells were restedovernight at 37°C, 5% CO2, and then stimulated with heat-killed B.
pertussis and a pertussis antigen cocktail consisting of pertactin (2
mg/ml), FHA (1 mg/ml) and pertussis toxin (1 mg/ml) for four hours
[37]. Optimisation experiments had shown that stimulation of PBMC
for a longer period of 18 h resulted in limited ability to detect intra-
cellular cytokine responses. Cultured cells were incubated with
20mM Ethylenediaminetetraacetic acid (EDTA) on ice for 20 min to
remove any cells that became adhered to the tissue culture plate sur-
face during stimulation. Cells were washed with PBS and stained
with the Zombie AquaTM Fixable Viability Kit for 15 min following
the manufacturer’s instructions (BioLegend, UK). Commercially vali-
dated antibodies for cell surface and intracellular staining were pur-
chased from BioLegend (UK) unless stated otherwise and were
titrated prior to use (Supplementary Table 1). No additional valida-
tion was performed in-house. Cultured cells were washed and
stained for 20 min to identify T cells (CD3Alexa Fluor 700, SK7,
#344822), B cells (CD19 PerCP/Cy5.5, HIB19, #302230), NK cells
(CD16 PE/Cy7, B73.1, #360708; CD56 Brilliant Violet 711TM, HCD56,
#318336; CD107a Brilliant Violet 421TM, H4A3, #328626), monocytes
(HLA-DR APC/FireTM 750, L243, #307658; CD16 PE/Cy7, B73.1,
#360708; CD14 Brilliant Violet 605TM, M5E2, #301834) and DCs
(HLA-DR APC/FireTM 750, L243, #307658; CD123 Brilliant Violet
785TM, 6H6, #306032; CD11c PE/DazzleTM 594, 3.9, #301642).
PBMCs were fixed (4% paraformaldehyde, BioLegend, UK) for
20 min at room temperature, and permeabilized (permeabilization
wash buffer, BioLegend, UK). Intracellular cytokine staining utilising
antibodies conjugated to PE for IFN-g (B27, #506506), IL-6 (MQ2-
13A5, #501107) and TNFa (MAb11, #502908), and conjugated to
APC for IL-10 (JES3-9D7, #501409), IL-1b (8516, Invitrogen, #MA5-
23597), and IL-12 (C11.5, #501809), was then performed. Fluores-
cence minus one (FMO) controls were included for all cytokines to
ensure accurate gating of positive populations. Samples were
acquired on a BD LSRFortessa Flow Cytometer and data analysed
with FlowJo, Version 10 (Tree Star, USA) and Cytobank (Cytobank Inc,
USA). A hierarchical gating strategy was used to identify innate cell
populations and cytokine producing cells (Supplementary Fig. 1),
excluding doublets and dead cells [38]. T cells (CD3+) and B cells
(CD19+) were gated out prior to innate immune cell subsetting. NK
cell subsetting identified cytokine producing (CD56brightCD16) and
cytotoxic (CD56dimCD16+) NK cells. Monocytes were identified by
expression of HLA-DR and subsetted as classical (CD14++CD16),
intermediate (CD14++CD16+) and non-classical (CD14+CD16++). HLA-
DR-expressing plasmacytoid and myeloid dendritic cells were identi-
fied by expression of CD123 and CD11c, respectively.
2.8. Statistical analysis
The study was a prospective, observational cohort study that was
not randomised nor blinded. A sample size calculation at each time
point was not performed. Maternal cytokine concentrations pro-
duced in response to B. pertussis in Tdap-IPV-vaccinated and unvacci-
nated groups were compared by Mann-Whitney U test or Student’s t
test, depending on the distribution of the data. For analysis of infant
responses, cytokine concentrations were log transformed (natural
log; Y=Ln(Y)) to achieve normality, and a random intercepts linear
regression model used to analyse the impact of maternal Tdap-IPV on
infant cytokine concentrations measured by ELISA/multiplex immu-
noassay at birth, seven weeks and five months of age, assuming that
the data are missing completely at random. The model included the
main effects of time and vaccination status, and a time by vaccination
interaction. The model accounted for variation in the random inter-
cepts of the individuals. The frequency of each monocyte subset (clas-
sical, intermediate, non-classical) within the monocyte population
was analysed by 2-way ANOVA (variables: vaccination status and in
vitro treatment). Cytokine levels measured by flow cytometry in cord
PBMCs were analysed by Student’s t-test or Mann-Whitney U test,
4 T.F. Rice et al. / EBioMedicine 72 (2021) 103612depending on the distribution of data. The Friedman test was used to
analyse cytokine responses to B. pertussis in the absence of blood
plasma compared to responses in the presence of plasma. A P value
<0.05 was considered statistically significant. The random intercepts
model was performed using Stata version 16, all other analyses were
conducted using GraphPad Prism v8.
2.9. Role of the funding source
This article is independent research funded by the National Insti-
tute for Health Research (NIHR) Imperial Biomedical Research Centre
(BRC) and the IMmunising PRegnant women and INfants neTwork
(IMPRINT) funded by the GCRF Networks in Vaccines Research and
Development, which was co-funded by the MRC and BBSRC. Neither
of these funders had a role in study design; in the collection, analysis,
and interpretation of data; in the writing of the report; nor in the
decision to submit the paper for publication.
3. Results
3.1. Study subjects
In total, samples from 21 mothers and 67 infants were included in
the study. Samples from vaccinated and unvaccinated pregnancies
were collected over similar time periods (Supplementary Tables
26). Due to the unpredictable timing of sample collection and the
need for the whole blood assay to be run on fresh blood, the majority
of infants were not included at every time point. Thus, missingness
was not related to the outcome measures. Overall, the whole blood
assay dataset consisted of 48 infants (40 at one timepoint, six infants
at two timepoints, and two infants at all three time points; Supple-
mentary Fig. 2). Clinical data for maternal and infant samples used in
the whole blood assay are shown in Supplementary Table 25.
Other than Tdap-IPV vaccination status, the two groups were
matched for all other variables, including age, BMI, ethnicity, parity,
gravidity, except for a higher rate of maternal influenza vaccination
for the samples run on seven-week-old infants born to Tdap-IPV-vac-
cinated mothers (p=0.024, Fisher’s exact test). For the flow cytometry
assay, cord blood samples from 20 individuals were included (one of
which was also used in the whole blood assay). Clinical data for the
pregnancies from which cord samples were used in the flow cytome-
try assay are described in Supplementary Table 6. There were no sig-
nificant differences between the groups for any variables, except for
Tdap-IPV vaccination status.
Following the switch from Repevax to Boostrix-IPV, we recorded
the vaccine brand administered to our recruits based on patient
recall. The majority (48/52) women had received Boostrix-IPV, with
three women for whom the vaccine brand was unknown. Three of
these pregnancies were in the group from which we obtained 5-
month-old infant vaccine samples, and one in the group from which
we performed flow analyses on cord PBMC. For these four patients,
vaccination was delivered at three, four, six and seven months after
the advised switch to Boostrix-IPV.
3.2. Tdap-IPV vaccination during pregnancy is associated with elevated
maternal cytokine responses to B. pertussis
To investigate whether Tdap vaccination modulates the innate
immune response to the causative bacterium of pertussis disease,
maternal blood from vaccinated and unvaccinated pregnancies was
incubated for 24 h with heat-killed B. pertussis bacteria and cytokine
release measured by multiplex immunoassay or ELISA. LPS served as
a positive control for the experiment, being a potent activator of
innate immune responses, primarily through toll-like receptor 4
(TLR-4). IL-6, IL-8, IL-10 and TNF-a responses were all significantly
higher in Tdap-IPV-vaccinated women, compared to unvaccinatedwomen (IL-6 866, 95% CI [318, 1930], p<0.01, Student’s t test; IL-8
9980, 95% CI [1111, 60922], p=0.03, Mann-Whitney U test; IL-10 21,
95% CI [-5.7, 68], p=0.03, Student’s t test; TNF-a 191, 95% CI [31, 358],
p=0.04, Mann-Whitney U test; Fig. 1). There was a non-significant
increase in the IL-1b and IL-12 response in Tdap-IPV-vaccinated
women (IL-1b 53, 95% CI [-0.8, 97], p=0.06, Mann-Whitney U test; IL-
12 1.4, 95% CI [-0.04, 2.1], p=0.07, Mann-Whitney U test; Fig. 1). IFN-
g , IL-2, IL-4 and IL-13 responses were unaffected by maternal Tdap
vaccination.
3.3. Maternal Tdap-IPV vaccination modifies infant cytokine responses
to B. pertussis
To determine the impact of maternal Tdap-IPV on infant cellular
responses to B. pertussis, cord blood, and blood from 7-week-old and
5-month-old infants was incubated with B. pertussis as for maternal
blood (Fig. 2; Table 1). LPS served as a positive control, as before. At
birth, IL-2 and IL-12 responses were significantly higher in infants
from Tdap-IPV-vaccinated pregnancies, compared to the unvacci-
nated group (IL-2 1.5, 95% CI [0.55, 2.47], p<0.01; IL-12p70 1.29, 95%
CI [0.56, 2.02], p<0.001, random intercepts model). At seven weeks
of age (prior to pediatric pertussis vaccination), infants from Tdap-
IPV-vaccinated pregnancies still had significantly elevated IL-2
responses to B. pertussis, compared to infants from unvaccinated
pregnancies (0.99, 95% CI [0.02, 2.00], p=0.045, random intercepts
model), but IL-12 was no longer significantly different (p=0.088). In
addition, IL-10 and IL-13 responses were decreased in the infants
from Tdap-IPV-vaccinated pregnancies, compared to those from
unvaccinated pregnancies (IL-10 -0.57, 95% CI [-1.11, 0.03], p=0.04;
IL-13 -1.07, 95% CI [-2.00, -0.15], p=0.02; random intercepts model;
Fig. 2; Table 1). At five months of age (one month after completion of
pediatric pertussis vaccination), the significantly reduced IL-10
response to B. pertussis was still seen in infants from Tdap-IPV-vacci-
nated pregnancies, as well as lower IL-4 (IL-4 -1.37, 95% CI [-2.53,
-0.22], p=0.02; IL-10 -0.60, 95% CI [-1.22, -0.05], p=0.03; random
intercepts model; Fig. 2; Table 1). All other cytokines (IFN-g , IL-1b,
IL-6, IL-8, IL-13 and TNF-a) were unaffected by maternal Tdap vacci-
nation.
To determine the contribution of antigen-specific maternal IgG
present on cytokine responses in infants, cord blood responses were
investigated in the absence of plasma. The removal of plasma from
cord blood resulted in significant reductions in the IL-1b (88%,
p<0.0001), IL-6 (75%, p<0.001) and IL-10 (76%, p<0.01) responses to
B. pertussis (Friedman test; Supplementary Fig. 3). However, these
responses were restored by replacement with cord blood serum from
either unvaccinated or Tdap-IPV-vaccinated pregnancies (p>0.05),
suggesting that the observed differences in cytokine responses
between the treatment groups cannot be attributed to the presence
of vaccination-induced maternally-derived pertussis-specific anti-
bodies.
3.4. Tdap-IPV vaccination during pregnancy is associated with altered
distributions of monocyte populations in infants at birth
In order to compare innate cell populations in infants born to
unvaccinated and Tdap-IPV-vaccinated women, PBMCs from cord
blood were stimulated with heat-killed B. pertussis as before, as well
as a mixture of pertussis antigens contained in the Tdap-IPV vaccine
administered to mothers (pertussis toxin, filamentous haemaggluti-
nin and pertactin) and then analysed by flow cytometry. LPS served
as a positive control. CD3+ T cells and CD19+ B cells were gated out
and three populations of monocytes were identified as classical
(CD14++CD16), intermediate (CD14++CD16+) and non-classical
(CD14+CD16++; Fig. 3a, Supplementary Fig. 1). PBMCs from babies
born to Tdap-IPV-vaccinated women contained significantly elevated
proportions of classical monocytes (75% of total monocyte
Fig. 1. Impact of maternal Tdap-IPV vaccination on maternal innate cytokine responses to
B. pertussis. Maternal blood was treated for 24 h with heat-killed B. pertussis in dupli-
cate and cytokines were quantified in supernatants in singlicate. Data points represent
cytokine concentrations plotted on a log10 scale. Unvaccinated n=10 (filled blue
circles); vaccinated n=11 (open green circles). Vaccinated and unvaccinated groups
were compared by Student’s t test (normal distribution; IL-6 and IL-10) or Mann-Whit-
ney U test (non-normal distribution; all others); * p<0.05, ** p<0.01. (For interpreta-
tion of the references to color in this figure legend, the reader is referred to the web
version of this article.)
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(62%, p=0.01, 2-way ANOVA; Fig. 3b). Similar differences were also
observed following vaccine-antigen stimulation (85% versus 74%,
p=0.01, 2-way ANOVA; Fig. 3b), but not following B. pertussis nor LPS
stimulation. In parallel, there was a reduction in the proportion of
intermediate monocytes in PBMCs from infants born to Tdap-IPV-
vaccinated women, compared to unvaccinated (19% versus 32%,
p<0.01, 2-way ANOVA). This difference was again seen following
antigen stimulation (11% versus 21%, p<0.01, 2-way ANOVA), but not
with bacteria or LPS stimulation.Fig. 2. Impact of maternal Tdap-IPV vaccination on infant innate cytokine responses to B. pertus
pertussis immunisation) and five months of age (5m; post-primary pertussis immunisation
quantified in supernatants in singlicate. Data points represent cytokine concentrations plotte
n=10, 7w n=10, 5m n=7 (filled blue circles and solid line). Vaccinated: cord n=11, 7w n=10,
p<0.01, *** p<0.01. (For interpretation of the references to color in this figure legend, the reaAt birth, no significant differences were observed between the treat-
ment groups for neonatal CD56Bright or CD56Dim NK cells under any of
the stimulation conditions (p>0.05; Fig. 3a,c). Tdap-IPV vaccination also
did not significantly alter the proportions of myeloid (CD11c+) nor plas-
macytoid (CD123+) dendritic cells (p>0.05; Fig. 3a,d).3.5. Tdap-IPV vaccination during pregnancy alters cytokine production
from monocytes and NK cells in infants at birth
In order to evaluate the impact of maternal Tdap-IPV on infant
innate immune cell function, IFN-g , IL-1b, IL-6, IL-10, IL-12 and TNF-
a production per cell subset were investigated by intracellular cyto-
kine staining following in vitro stimulation with B. pertussis and
Tdap-IPV vaccine antigens in cord blood PBMC (Fig. 4). Maternal
Tdap-IPV vaccination did not significantly impact the levels of cyto-
kines in cord blood intermediate and non-classical monocytes (Sup-
plementary Fig. 4). This was also the case for classical monocytes,
with the exception of IL-12 which was reduced in the Tdap-IPV-vac-
cinated group, compared to the unvaccinated group (-2.0, 95% CI
[-4.0, 0.1], p=0.03, Mann-Whitney U test; Fig. 4a). In CD56Bright NK
cells, a 1.4-fold lower IFN-g response to B. pertussis was observed in
infants born to Tdap-IPV-vaccinated women, compared to unvacci-
nated (-3.5, 95% CI [-5.1, -0.7], p=0.02, Mann-Whitney U test; Fig. 4b).
There were no significant differences in proportion of NK cells posi-
tive for TNF-a. Cytokine levels in myeloid and plasmacytoid DCs were
generally low in response to all treatments, regardless of vaccination
status. There was an increase in TNF-a in the unvaccinated group in
response to Tdap-IPV vaccine antigens in myeloid DCs (-6.6, 95% CI
[-12.2, 0.1], p=0.03, Mann-Whitney U test; Supplementary Fig. 5).
Tdap-IPV vaccination did not impact cytokine levels in myeloid nor
plasmacytoid DCs, whether cells were left untreated or were exposed
to B. pertussis or Tdap-IPV vaccine antigens, for all other cytokines
(Supplementary Fig. 5). Whilst some cytokines were also found in T
cells and B cells, no significant differences were observed between
unvaccinated and Tdap-IPV-vaccinated groups in response to B.sis. Blood from the umbilical cord (0) and from infants at seven weeks (7w; pre-primary
) was treated with B. pertussis for 24 h in duplicate and cytokine concentrations were
d on a log2 scale and error bars represent the standard error mean. Unvaccinated: cord
5m n=10 (open green circles and dashed line). Random intercepts model; * p<0.05, **
der is referred to the web version of this article.)
Table 1
Impact of maternal Tdap-IPV on infant cytokine responses to B. pertussis. Whole blood cytokine responses to
B. pertussis in infants from Tdap-IPV-vaccinated and unvaccinated pregnancies at birth, seven weeks and
five months of age were measured by multiplex cytokine assay/ELISA. Table shows the predicted means of
log-transformed outcomes, and the results of these when used in a random intercepts linear regression
model to compare cytokine responses in infants from Tdap-IPV-vaccinated and unvaccinated pregnancies
at each time point. Positive contrasts denote higher responses in the vaccinated group compared to the
unvaccinated group, and negative coefficients denote lower responses. SE; standard error, 95%CI; 95% con-
fidence intervals, p values <0.05 indicated in bold.
Age Cytokine Unvaccinated Vaccinated Contrast (SE) 95%CI P value
Birth IFN-y 4.66 4.38 -0.27 (0.54) -1.33, 0.78 0.6103
IL-1b 5.47 5.08 -0.39 (0.31) -1.00, 0.22 0.2129
IL-2 -2.13 -0.62 1.51 (0.49) 0.55, 2.47 0.0021
IL-4 0.83 1.10 0.27 (0 .53) -0.76, 1.30 0.6048
IL-6 7.91 8.23 0.31 (0.24) -0.15, 0.78 0.1891
IL-8 199.38 179.57 -19.81 (23.15) -65.18, 25.56 0.3922
IL-10 4.03 4.07 0.05 (0.29) -0.51, 0.61 0.8646
IL-12 1.27 2.56 1.29 (0.37) 0.56, 2.02 0.0005
IL-13 2.60 2.88 0.28 (0.48) -0.66, 1.22 0.5627
TNF-a 5.98 5.98 0.001 (0.31) -0.61, 0.61 0.9969
7 weeks IFN-y 6.24 6.45 0.21 (0.52) -0.81, 1.23 0.6853
IL-1b 5.84 5.90 0.06 (0.31) -0.55, 0.66 0.8541
IL-2 0.00 1.00 0.99 (0.50) 0.02, 2.00 0.0451
IL-4 0.41 0.66 0.25 (0.54) -0.80, 1.30 0.6380
IL-6 8.30 7.99 -0.32 (0.24) -0.78, 0.15 0.1877
IL-8 133.92 119.98 -13.94 (23.34) -59.68, 31.80 0.5503
IL-10 4.56 3.98 -0.57 (0.28) -1.11, 0.03 0.0384
IL-12 1.68 1.08 -0.61 (0.37) -1.31, 0.09 0.0880
IL-13 2.46 1.39 -1.07 (0.47) -2.00, -0.15 0.0226
TNF-a 7.27 7.11 -0.16 (0.32) -0.78, 0.46 0.6091
5 months IFN-y 7.10 6.77 -0.32 (0.56) -1.42, 0.78 0.5658
IL-1b 5.21 5.35 0.14 (0.33) -0.52, 0.79 0.6827
IL-2 2.47 1.43 -1.05 (0.55) -2.12, 0.027 0.0560
IL-4 2.62 1.24 -1.37 (0.59) -2.53, -0.22 0.0199
IL-6 7.79 7.42 -0.37 (0.26) -0.88, 0.14 0.1553
IL-8 138.45 106.91 -31.54 (25.57) -81.65, 18.56 0.2173
IL-10 4.50 3.86 -0.64 (0.30) -1.22 - -0.05 0.0321
IL-12 2.31 1.96 -0.36 (0.38) -1.10 - 0.39 0.3512
IL-13 2.13 2.32 0.19 (0.51) -0.81 - 1.19 0.7110
TNF-a 6.58 6.48 -0.10 (0.35) -0.78 - 0.58 0.7726
6 T.F. Rice et al. / EBioMedicine 72 (2021) 103612pertussis nor the Tdap-IPV vaccine antigens (all p>0.05; Supplemen-
tary Fig. 6).
4. Discussion
Pertussis vaccination during pregnancy boosts anti-pertussis anti-
body levels in both mothers and their offspring, and prevents pertus-
sis disease in infants [1721]. Several studies have demonstrated
that Tdap/Tdap-IPV vaccination in pregnancy is associated with
reduced humoral responses to pediatric pertussis vaccination in the
offspring [1720]. Whether there is also any impact of maternal per-
tussis vaccination on infant cell-mediated immunity is largely
unknown. The only study published to date looked at cord blood B
cell, T cell and whole blood cytokine responses to B. pertussis and
found no effect of maternal Tdap on any of these parameters [22].
Here, we have assessed the impact of maternal Tdap-IPV on cellular
responses to B. pertussis at birth and infancy; both before and after
receipt of paediatric pertussis vaccination. We found that Tdap-IPV
vaccination in pregnancy is associated with modulation in cytokine
responsiveness in both women and their babies, and altered pheno-
type and function of infant innate immune cell responses to B. pertus-
sis. We propose that these changes to cell-mediated immunity may
contribute to the altered humoral response to pertussis vaccines seen
in babies from Tdap-IPV-vaccinated pregnancies.
Our findings suggest that recently Tdap-IPV-vaccinated pregnant
women may be primed to mount a greater innate cytokine response
to B. pertussis. Tdap-IPV vaccination was associated with elevated in
vitrowhole blood cytokine responses to B. pertussis in maternal blood
at birth, with higher production of IL-6, IL-8, IL-10 and TNF-a; cyto-
kines associated with both pro- and anti-inflammatory responses.Pertussis antigens contained in the Tdap-IPV vaccine have been pre-
viously shown to induce cytokine production in vitro; FHA induces
TNF-a production in human monocyte-derived macrophages [39]
and stimulates the production of IL-10 and IL-6 in mouse macro-
phages and DCs [26,30]. In addition, this effect could be due to the
presence of pertussis-specific T cells in Tdap-IPV-vaccinees, given the
role for T cells in regulating early innate inflammatory responses
[4043].
The offspring of Tdap-IPV-vaccinated women also exhibited
altered cell-mediated immune responses to B. pertussis. Babies from
Tdap-IPV pregnancies had elevated IL-2 and IL-12p70 whole blood
responses to B. pertussis at birth. The production of IL-12 by innate
cells during B. pertussis infection enables the polarisation of the T cell
response, to the T helper type 1 (Th1) subtype [44]. IL-2 acts primarily
as a T cell growth factor, essential for the proliferation and survival of
T cells, and is mainly produced by activated CD4+ T cells, also in
response to B. pertussis [45,46]. At birth, all other whole blood cyto-
kine responses were unchanged, suggesting a circumscribed modula-
tion of the neonatal immune system by maternal Tdap-IPV.
In infants at birth, we additionally characterised innate immune
cell subsets and their cytokine response by flow cytometry. Mono-
cytes transition from classical, to intermediate, to non-classical, with
the non-classical monocytes comprising the mature subset [47]. Cord
blood PBMC from Tdap-IPV-vaccinated pregnancies contained a
higher proportion of classical monocytes and reduced frequency of
intermediate monocytes in both resting conditions and following
exposure to Tdap-IPV vaccine antigens. The mechanism of this rather
striking observation is unclear. Observed differences were not due to
in vitro adherence of activated monocytes; polypropylene was used
throughout for PBMC assays and EDTA used to detach any potential
Fig. 3. Modulation of cord blood innate cell populations by maternal Tdap. Cord peripheral mononuclear cells were stimulated for four hours with B. pertussis (Bp) or acellular pertussis
vaccine antigens (Ag) and innate cell populations identified by flow cytometry. (a) tSNE analysis of the expression of surface markers on cord peripheral mononuclear cells from
unvaccinated and Tdap-IPV-vaccinated pregnancies. (b) Monocyte subsets were identified by the expression of CD14 and CD16 and compared between groups and treatment by 2-
way ANOVA. (c) NK cell subsets were identified by the expression of CD56 and CD16. In CD56Bright NK cells, vaccinated and unvaccinated groups were compared by Student’s t test
(normal distribution; NT) or Mann-Whitney U test (non-normal distribution; all others) and no significant differences were observed between groups. In CD56Dim NK cells, vacci-
nated and unvaccinated groups were compared by Mann-Whitney U test and no significant differences were observed groups. (d) DC subsets were identified by the expression of
CD11c and CD123. In mDCs, vaccinated and unvaccinated groups were compared by Mann-Whitney U test and no significant differences were observed groups. In pDCs, vaccinated
and unvaccinated groups were compared by Student’s t test (normal distribution; NT, LPS and Bp) or Mann-Whitney U test (non-normal distribution; Ag) and no significant differ-
ences were observed between groups. Error bars represent the standard deviation from the mean. For all analyses unvaccinated and Tdap-IPV groups n=10. UV: unvaccinated; V:
vaccinated; NT: no stimulation; Bp: B. pertussis; LPS: lipopolysaccharide; Ag: antigen; * p<0.05.
T.F. Rice et al. / EBioMedicine 72 (2021) 103612 7adherent cells. Myeloid cells originate in the fetal circulation as early
as three weeks gestation [48] which has been proposed to make
them potentially susceptible to reprogramming by the maternal envi-
ronment [49]. Interestingly, this difference in monocyte distributions
between vaccinated and unvaccinated groups was not observed fol-
lowing B. pertussis nor LPS exposure, suggesting that any Tdap-IPV-
induced differences in the distribution of monocyte populations in
infants at birth are likely to be lost upon pathogen encounter. As
CD16 is essential for monocyte antibody-dependent cellular cytotox-
icity (ADCC) [50] and an increase in the proportion of monocytes
lacking CD16 may have implications for the neonatal innate immune
response, it would be valuable to monitor these responses across the
neonatal period and in infancy to ascertain if indeed this represents a
more long-lasting effect on monocyte populations.
Unlike the higher IL-12 whole blood responses in neonates from
vaccinated pregnancies, the proportion of IL-12-positive monocytes
following B. pertussis stimulation were lower, suggesting that IL-12 in
the whole blood assay originated from other cellular sources, such as
neutrophils. We did not investigate neutrophils by flow cytometry,as they are strongly affected by cryopreservation. The proportion of
IFN-g-positive NK cells was also lower in neonates from vaccinated
pregnancies. Innate IL-12 and IFN-g are important in the immune
response to B. pertussis infection. Both cytokines help to polarise the
T cell response [25] and IFN-g localises B. pertussis to the lungs in ani-
mals models [23,24] as well as enhancing the killing of B. pertussis by
macrophages. Unlike the whole blood assay, the PBMC stimulations
lacked plasma (and thus maternal IgG). Several immune cells express
receptors for the Fc domain of IgG, and interactions between anti-
body:antigen complexes with Fc receptors on immune cells modulate
the innate and adaptive immune response. For example, during anti-
body-dependent cellular cytotoxicity (ADCC), cytokine production
can be triggered in NK cells through binding of antibody that has
opsonised its target to NK cell Fc receptors [51]. Although removal of
plasma from the whole blood assay reduced the cytokine response to
B. pertussis, it was restored by replacement with serum from both
Tdap-IPV-vaccinated and unvaccinated pregnancies, suggesting that
the differences observed were not solely due to higher levels of
maternal anti-pertussis IgG in babies from vaccinated pregnancies.
Fig. 4. Modulation of cord blood monocyte and NK cell cytokine levels by maternal Tdap-
IPV. Cord peripheral mononuclear cells were stimulated for four hours with B. pertussis
(Bp) or acellular pertussis vaccine antigens (Ag) and cytokine levels determined by
flow cytometry. (a) In classical monocytes vaccinated and unvaccinated groups were
compared by Student’s t test (normal distribution; IL-6 and IL-1b) or Mann-Whitney U
test (non-normal distribution; all others). (b) In CD56Bright NK cells vaccinated and
unvaccinated groups were compared by Mann-Whitney U test. For all analyses unvac-
cinated and Tdap-IPV groups n=10; UV: unvaccinated; V: vaccinated; NT: no stimula-
tion; Bp: B. pertussis; Ag: antigen; * p<0.05.
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response to B. pertussis in infants at seven weeks (pre-pertussis
immunisation) and five months of age (post-primary immunisation)
in whole blood in order to explore the potential for longer-term
effects of maternal Tdap-IPV. As was observed at birth, infants from
Tdap-IPV-vaccinated pregnancies had increased IL-2 responses at
seven weeks of age, compared to infants from unvaccinated pregnan-
cies. As described earlier, IL-2 acts as a T cell growth factor [45,46]
and its elevation in infants at seven weeks of age may enhance the
expansion and activation of T cells that are primed by subsequent pri-
mary pertussis immunisation. However, the clinical consequences in
the context of infection or vaccination remains to be established.During B. pertussis infection, T helper cells polarise towards a (Th)
1 cytokine response, [45,46] that enables the killing of bacteria. In
contrast, following acellular pertussis vaccination there is the induc-
tion of Th2 cytokines, suggesting a skewing of the T cell response
[52,53]. In the present study, there were decreases in the cytokine
response to B. pertussis in infants from Tdap-IPV-vaccinated pregnan-
cies at seven weeks and/or five months of age for IL-4, IL-10 and IL-
13, compared to the unvaccinated group. These cytokines are nor-
mally associated with Th2 responses, which following acellular per-
tussis vaccination are not associated with protective immunity
against pertussis in animal models [54]. The decrease in IL-10
responses observed in infants at seven weeks and five months of age
from Tdap-IPV-vaccinated pregnancies is in direct contrast to the
effect seen in the mothers, where Tdap-IPV-vaccination was associ-
ated with elevated IL-10 responses to the bacteria. IL-10 primarily
acts as an anti-inflammatory cytokine and can inhibit the activity of
NK cells, T helper 1 cells and macrophages [55]. IL-10 from innate
cells has previously been shown to reduce B. pertussis-specific pro-
inflammatory responses in infants that received an acellular pertussis
vaccine [56]. Innate immune cells have the capacity to secrete IL-10
[25] and given the short incubation period after which supernatants
were harvested these are the most likely source. Our data suggests
that maternal Tdap-IPV vaccination in pregnancy has a longer lasting
effect on the IL-10 response to B. pertussis in the offspring, which
may play a role in inhibiting pertussis vaccine responses in infants.
However, the biological consequences of this small, though signifi-
cant reduced IL-10 response, remains to be fully determined.
The mechanisms behind our observed effects of maternal pertus-
sis vaccination on infant cell-mediated immunity is currently not
known. The developmental origins of health and disease (DoHaD)
hypothesis postulates that in utero exposure to environmental influ-
ences during critical periods of development may impact on short
and long-term health of the offspring [57]. Maternal vaccination,
which induces a maternal immune response is one such intervention.
Maternal cytokines produced in response to vaccination could poten-
tially cross the placenta directly to modify neonatal responses at
birth: studies utilising a placental perfusion model to study cytokine
transfer have produced conflicting results; one study concluded that
maternal IL-6 may cross the placenta [58] whilst another study found
that it does not [59]. Both studies only investigated pro-inflammatory
cytokines (IL-6, TNF-a, IL-1a/b), and it is not known if other cyto-
kines such as IL-10 can cross into the fetal circulation to modulate
the fetal immune system. Furthermore, in utero exposure to antigens
has been associated with altered immune responses at birth [60]
potentially facilitated through passage of antigen-antibody com-
plexes across the placenta [61].
Our study subjects were recruited when maternal vaccination in
the UK was recommended between 2832 weeks gestation [62]
which is reflected in our mean of 30.9 weeks gestation (mode 30
weeks) of maternal vaccination across all our subjects. Since April
2016, the vaccine has been recommended to be administered
between 1632 weeks [63] partly due to reports that cord blood
antibody levels may be higher when women are vaccinated in the
second trimester [64] and to better protect babies that deliver pre-
term. It would therefore be of interest to determine whether earlier
gestation at Tdap-IPV vaccine administration also has a greater effect
on offspring cellular immune responses.
Our study has some limitations. The flow cytometry assays were
only performed on cord blood due to the sample volume require-
ment. Therefore, the flow data only reflects the infant immune sys-
tem at birth, and future studies should investigate whether maternal
Tdap-IPV has a longer-lasting effect on infant monocyte populations.
Flow cytometry was performed on cryopreserved PBMC, which
enabled us to analyse batched vaccinated and unvaccinated samples,
reducing technical and reagent variation, but this could have
impacted the expression of activation markers and cytokine
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vaccination, but some women may have received a different brand
(Repevax). As the vaccine was delivered through primary care at
this time, the brand administered was not recorded in hospital
records, and so we relied on patient recall. We therefore had some
patients (4/52) with unknown vaccine brands, although these were
all vaccinated after the switch to Boostrix-IPV, so it is probable that
all of the patients in this study did receive the same vaccine. For these
reasons, we were unable to investigate any potential differences in
responses to different Tdap-IPV vaccine formulations. As infants also
receive their primary immunisations through primary care, we were
not able to access information on the brand of vaccine they had
received, and hence could not compare responses between infants
that had received a primary course of either Pediacel or Infanrix-
IPV-Hib. Although as of 2017, all infants in the UK are now offered
the 6-in-1 vaccine Infanrix hexa as their primary pertussis vaccine.
Further, we did not assess cytokine responses to B. pertussis in non-
pregnant females, to help elucidate any potential effects of pregnancy
on the innate immune response to B. pertussis. As pertussis vaccina-
tion is recommended during pregnancy by health authorities in the
UK, a randomized control trial with a no-vaccine arm was not possi-
ble due to ethical reasons. Therefore, unvaccinated pregnant women
in this study did not receive Tdap-IPV for a variety of reasons, includ-
ing through their own choice or because they were unaware of
the recommendation, as we have previously described in this popula-
tion [65].
In conclusion, maternal Tdap-IPV vaccination may be associ-
ated with altered monocyte subsets at birth and reduced mono-
cytic IL-12 and NK cell IFN-g responses to B. pertussis (in the
absence of IgG), pointing towards the intriguing possibility that
maternal Tdap-IPV may lead to additional in utero modification of
the fetal immune system, beyond effects mediated by IgG transfer
alone. In the whole blood assay, we conversely saw elevated IL-2
and IL-12 at birth. Importantly, levels of IL-2 remained elevated
at seven weeks of age and could therefore play a role in modula-
tion of T cell function in these infants. Other than elevated IL-2,
maternal Tdap-IPV otherwise resulted in a reduction in Th2 cyto-
kine responses (IL4, IL-10, IL-13) in blood from older infants,
which could play a role in the reduced humoral response that
has been observed in infants from Tdap/Tdap-IPV-vaccinated
pregnancies. [1720] Any clinical relevance of these observations
in terms of infant responses to infection or vaccination remains
to be established. Given that certain vaccines may also have non-
specific effects through epigenetic reprogramming of innate cells
[66,67] - a concept termed trained immunity - future studies
should investigate whether maternal Tdap-IPV vaccination during
pregnancy might alter gene expression in fetal immune cells.
Although it is important to note that to date, vaccines shown to
demonstrate trained immune effects on the innate immune sys-
tem have all been live vaccines. In the meantime, vaccination of
pregnant women against pertussis has already prevented many
cases of pertussis in young infants [1012]. These interesting
immunological findings need to be interpreted in the context of
proven vaccine benefit to mothers and babies.5. Contributors
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